Alt Text

QIAreach™ Antigen and Antibody Tests: Fighting the COVID-19 Pandemic

In partnership with QIAGEN®, Ellume has accelerated the development of two rapid, reliable COVID-19 tests to support the global response to the coronavirus pandemic.

The QIAreach™Anti-SARS-CoV-2 Total Test, is a high-performance serological test which detects antibodies in people who have been exposed to SARS-CoV-2. The test was submitted for US FDA Emergency Use Authorization (EUA) in August 2020.

The QIAreach™ Anti-SARS-CoV-2 Antigen Test detects SARS-CoV-2 antigens in people with active infections. QIAGEN has applied for US FDA Emergency Use Authorization and will seek CE-IVD registration in Europe.

Alt Text

Key Features

  • Early positive results from 3 minutes
  • Simple testing process
  • Minimal training requirements
  • Single patient visit
  • Objective automated test result
  • No device calibration or maintenance required
  • No cold chain required
  • No continuous power supply required
  • No computer access required

Coronavirus: The Facts

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. COVID-19 is a respiratory illness primarily spread from person to person. COVID-19 symptoms can range from mild (or no symptoms) to severe illness. There are currently more than 21 million* confirmed cases globally with >775,000 deaths*. With no specific vaccines or treatments currently available for COVID-19, rapid diagnosis is pivotal to minimising transmission.

* Last update: 20 August 2020 – https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Sign up for our Newsletter

* indicates required